HB9 Inhibitors
HB9 inhibitors comprise a diverse group of compounds targeting various signaling pathways crucial for neural development. These inhibitors act either directly on HB9 or indirectly through modulation of associated pathways. ATRA, a retinoic acid analog, influences HB9 expression by activating retinoic acid receptors, orchestrating downstream events in the retinoic acid signaling pathway that impact neural differentiation. DAPT, a gamma-secretase inhibitor, disrupts Notch signaling crucial for HB9 interaction, indirectly inhibiting HB9 by interfering with this pivotal pathway. SB431542 selectively inhibits the TGF-β type I receptor, indirectly affecting HB9 expression as TGF-β pathways intricately regulate neural differentiation. XAV939, a tankyrase inhibitor, modulates Wnt signaling, indirectly impacting HB9 expression given its association with Wnt pathways in neural differentiation. LY294002, a PI3K inhibitor, disrupts the PI3K-Akt signaling pathway crucial for neural development, indirectly inhibiting HB9 by altering the activation of this pathway. U0126, a MEK inhibitor, indirectly modulates HB9 expression by affecting the MAPK pathway, essential for neural differentiation. SP600125, a JNK inhibitor, influences HB9 expression by disrupting JNK signaling, a pathway intricately linked to neurogenesis.
Rapamycin, a mTOR inhibitor, indirectly modulates HB9 expression by interfering with mTOR signaling, pivotal in neuronal differentiation. PD98059, another MEK inhibitor, indirectly influences HB9 expression by impacting the MAPK pathway essential for neural development. Wortmannin, a PI3K inhibitor, disrupts the PI3K-Akt pathway, indirectly inhibiting HB9 by altering the activation of this critical signaling pathway. H89, a PKA inhibitor, indirectly modulates HB9 expression by blocking PKA activity, impacting downstream signaling events crucial for neural differentiation. CHIR99021, a GSK-3 inhibitor, modulates Wnt signaling, indirectly influencing HB9 expression through its association with Wnt pathways in neural differentiation. The diverse mechanisms of these HB9 inhibitors highlight the intricate network of signaling pathways influencing HB9 expression during neural development.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
ATRA inhibits HB9 indirectly by modulating the retinoic acid signaling pathway. ATRA activates retinoic acid receptors (RARs), which influence downstream genes involved in neural differentiation, thus impacting HB9 expression. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT acts as a gamma-secretase inhibitor, affecting the Notch signaling pathway. Since HB9 interacts with Notch signaling during neurogenesis, DAPT indirectly inhibits HB9 by disrupting this crucial interaction. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is a selective inhibitor of the TGF-β type I receptor, suppressing TGF-β signaling. As HB9 is influenced by TGF-β pathways, SB431542 indirectly inhibits HB9 expression by blocking the activation of its associated signaling pathways. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV939 is a tankyrase inhibitor that modulates the Wnt signaling pathway. By disrupting Wnt signaling, XAV939 indirectly influences HB9 expression, as Wnt pathways are intricately linked to the regulation of neural differentiation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that disrupts the PI3K-Akt signaling pathway. Since Akt signaling plays a role in neural development, LY294002 indirectly inhibits HB9 expression by interfering with the activation of this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor affecting the JNK signaling pathway. As JNK pathways play a role in neurogenesis, SP600125 indirectly inhibits HB9 expression by disrupting the activation of JNK signaling, influencing the expression of HB9. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key player in the mTOR signaling pathway. Given the role of mTOR in neuronal differentiation, Rapamycin indirectly modulates HB9 expression by interfering with the activation of the mTOR pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective MEK inhibitor affecting the MAPK pathway. By inhibiting MEK, PD98059 indirectly influences HB9 expression, as the MAPK pathway plays a vital role in neural differentiation, impacting the expression of HB9. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that disrupts the PI3K-Akt signaling pathway. As Akt signaling is involved in neural development, Wortmannin indirectly inhibits HB9 expression by interfering with the activation of this pathway. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
CHIR99021 is a GSK-3 inhibitor that modulates the Wnt signaling pathway. By inhibiting GSK-3, CHIR99021 indirectly influences HB9 expression, as Wnt pathways are intricately linked to the regulation of neural differentiation. | ||||||